Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1471-4159
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Following induction of acute neuroinflammation by intracisternal injection of endotoxin (lipopolysaccharide) in rats, quantitative autoradiography was used to assess the regional level of microglial activation and glutamate (NMDA) receptor binding. The possible protective action of the antioxidant phenyl-tert-butyl nitrone in this model was tested by administering the drug in the drinking water for 6 days starting 24 hafter endotoxin injection. Animals were killed 7 days post-injection and consecutive cryostat brain sections labeled with [3H]PK11195 as a marker of activated microglia and [125I]iodoMK801 as a marker of the open-channel, activated state of NMDA receptors. Lipopolysaccharide increased [3H]PK11195 binding in the brain, with the largest increases (two- to threefold) in temporal and entorhinal cortex, hippocampus, and substantia innominata. A significant (〉 50%) decrease in [125I]iodoMK801 binding was found in the same brain regions. Phenyl-tert-butyl nitrone treatment resulted in a partial inhibition (approx. 25% decrease) of the lipopolysaccharide-induced increase in [3H]PK11195 binding but completely reversed the lipopolysaccharide-induced decrease in [125I]iodoMK80 binding in the entorhinal cortex, hippocampus, and substantia innominata. Loss of NMDA receptor function in cortical and hippocampal regions may contribute to the cognitive deficits observed in diseases with a neuroinflammatory component, such as meningitis or Alzheimer's disease.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Phytochemistry 20 (1981), S. 2436-2438 
    ISSN: 0031-9422
    Keywords: Phytolacca octandra ; Phytolaccaceae ; methyl acetyl serjanate ; methyl acetyl-11-keto serjanate. ; methyl serjanate ; methyl-3-keto serjanate
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Oxford, UK : Munksgaard International Publishers
    Allergy 57 (2002), S. 0 
    ISSN: 1398-9995
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Oxford, UK : Munksgaard International Publishers
    Allergy 60 (2005), S. 0 
    ISSN: 1398-9995
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Electronic Resource
    Electronic Resource
    Oxford, UK : Blackwell Publishing Ltd
    Annals of the New York Academy of Sciences 698 (1993), S. 0 
    ISSN: 1749-6632
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Natural Sciences in General
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Electronic Resource
    Electronic Resource
    Springer
    Advances in contraception 5 (1989), S. 57-70 
    ISSN: 1573-7195
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Resumé Au cours d'une étude clinique effectuée avec un nouveau progestogène, un mélange de 0,15 mg de désogestrel et de 0,03 mg d'éthinylestradiol a été administré cycliquement pendant 21 jours; 632 cycles ont été évalués chez 56 femmes. Les effets secondaires constatés ont été peu fréquents et en général bénins. Les pertes sanguines mensuelles étaient normales et présentes dans tous les cycles. Chez les patientes dont les cycles menstruels étaient irréguliers, ceux-ci se sont normalisés à 28/29 jours. On a constaté quelques cas isolés d'écoulement sanguin intermenstruel (traces) pour 16 cycles. Le symptôme le plus fréquent, la mastose, a disparu spontanément chez la plupart des patientes. Dans 2 cas seulement il a été nécessaire d'interrompre le traitement en raison d'effets secondaires. L'effet contraceptif s'est avéré excellent: aucune grossesse ne s'est produite. On a retrouvé une action progestative évidente dans le mucus cervical et l'endomètre. Les patientes qui souffraient d'acné en début de traitement ont constaté une amélioration sensible. Dans les cas bénins, l'acné a disparu complètement. On a également constaté une assez bonne amélioration de l'hirsutisme. Les variations pondérales n'ont pas atteint des proportions significatives. Les examens biochimiques ont révélé une augmentation de HDL-C et une diminution du rapport LDL-C/HDL-C. Aucune variation du cholestérol et des triglycérides n'est apparue, ce qui pourrait indiquer un moindre risque cardiovasculaire.
    Abstract: Resumen Se efectuó un estudio clínico con un nuevo progestágeno: 0,15 mg de desogestrol asociado con 0,03 mg de etinilestradiol, administrado cíclicamente durante 21 días; fueron evaludos 632 ciclos en 56 mujeres. Los effectos colaterales fueron escasos y, generalmente, moderados. El sangrado mensual fué normal y ocurrió en todos los ciclos. Las pacientes con ciclos irregulares se normalizaron en 28 a 29 días. En 16 cicios el sangrado intermenstrual (manchado) fué un episodio aislado. El síntoma mas frecuente, la mastalgia, desaparecio espontánesmente en la mayoria de las pacíentes. Solamente en dos casos nubo necesidad de suspender la medicación debido a los efectos colaterales. El efecto anticonceptivo fué excelente: no hubo ningun embarazo. El efecto progestacional fué evidente en el moco cervical y en al endometrio. Las pacientes con acné que iniciaron el tratamiento mejoraron notablemente. En los casos moderados el acné desapareció completamente. Se noté una discreta mejoría en el hirsutismo. Las variaciones en peso no fueron significatives. Estudios bioquímieos revelaron un aumento on HDL-C y una disminución on la relación LDL-C/HDL-C. El colesterol y los triglicéridos no mostraron variaciones lo que podría indicar menor ricsgo cardiovascular.
    Notes: Abstract A clinical study was performed with a new progestogen, desogestrel, in a 0.15 mg dose associated with 0.03 mg of ethinylestradiol and was administered cyclically during 21 days; 632 cycles were evaluated in 56 women. Side-effects were scarce and generally of a mild nature. Monthly bleeding was normal and present in all cycles. Patients with irregular cycles were normalized to 28/29 days. The intermenstrual bleeding (spotting) was an isolated event in 16 cycles. Mastalgia, the most frequent symptom, disappeared spontaneously in the majority of patients. In only 2 cases was it necessary to stop medication because of side-effects. The contraceptive effect was excellent; no pregnancies occurred. A progestative effect was evident in the cervical mucus and the endometrium. The patients who started treatment with acne improved noticeably. In the mild cases, acne disappeared completely. A discrete improvement in hirsutism was reported. The body-weight variation was not significant. Biochemical studies revealed an increase in HDL-C and a decrease in the ratio LDL-C/HDL-C. Cholesterol and triglycerides did not show variations, which could indicate a lesser cardiovascular risk.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...